241 related articles for article (PubMed ID: 35280813)
21. Evaluation of a multiparametric MRI radiomic-based approach for stratification of equivocal PI-RADS 3 and upgraded PI-RADS 4 prostatic lesions.
Brancato V; Aiello M; Basso L; Monti S; Palumbo L; Di Costanzo G; Salvatore M; Ragozzino A; Cavaliere C
Sci Rep; 2021 Jan; 11(1):643. PubMed ID: 33436929
[TBL] [Abstract][Full Text] [Related]
22. Utility of machine learning of apparent diffusion coefficient (ADC) and T2-weighted (T2W) radiomic features in PI-RADS version 2.1 category 3 lesions to predict prostate cancer diagnosis.
Lim CS; Abreu-Gomez J; Thornhill R; James N; Al Kindi A; Lim AS; Schieda N
Abdom Radiol (NY); 2021 Dec; 46(12):5647-5658. PubMed ID: 34467426
[TBL] [Abstract][Full Text] [Related]
23. Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center.
Hermie I; Van Besien J; De Visschere P; Lumen N; Decaestecker K
Eur J Radiol; 2019 May; 114():92-98. PubMed ID: 31005183
[TBL] [Abstract][Full Text] [Related]
24. Based on PI-RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4-20 ng/mL.
Huang H; Liu Z; Ma Y; Shao Y; Yang Z; Duan D; Zhao Y; Wen S; Tian J; Liu Y; Wang Z; Yue D; Wang Y
Prostate; 2024 Mar; 84(4):376-388. PubMed ID: 38116741
[TBL] [Abstract][Full Text] [Related]
25. Machine learning-based radiomics model to predict benign and malignant PI-RADS v2.1 category 3 lesions: a retrospective multi-center study.
Jin P; Shen J; Yang L; Zhang J; Shen A; Bao J; Wang X
BMC Med Imaging; 2023 Mar; 23(1):47. PubMed ID: 36991347
[TBL] [Abstract][Full Text] [Related]
26. Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy.
Yang S; Zhao W; Tan S; Zhang Y; Wei C; Chen T; Shen J
Transl Androl Urol; 2020 Jun; 9(3):1252-1261. PubMed ID: 32676408
[TBL] [Abstract][Full Text] [Related]
27. The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics.
Liu Y; Wang S; Xiang LH; Xu G; Dong L; Sun Y; Ye B; Zhang Y; Xu H
Br J Radiol; 2022 Sep; 95(1138):20220209. PubMed ID: 35877385
[TBL] [Abstract][Full Text] [Related]
28. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
[TBL] [Abstract][Full Text] [Related]
29. Development and external validation of a novel nomogram to predict prostate cancer in biopsy-naïve patients with PSA <10 ng/ml and PI-RADS v2.1 = 3 lesions.
Hu C; Sun J; Xu Z; Zhang Z; Zhou Q; Xu J; Chen H; Wang C; Ouyang J
Cancer Med; 2023 Feb; 12(3):2560-2571. PubMed ID: 35920264
[TBL] [Abstract][Full Text] [Related]
30. Predicting the Grade of Prostate Cancer Based on a Biparametric MRI Radiomics Signature.
Zhang L; Zhe X; Tang M; Zhang J; Ren J; Zhang X; Li L
Contrast Media Mol Imaging; 2021; 2021():7830909. PubMed ID: 35024015
[TBL] [Abstract][Full Text] [Related]
31. Bi-parametric magnetic resonance imaging based radiomics for the identification of benign and malignant prostate lesions: cross-vendor validation.
Ji X; Zhang J; Shi W; He D; Bao J; Wei X; Huang Y; Liu Y; Chen JC; Gao X; Tang Y; Xia W
Phys Eng Sci Med; 2021 Sep; 44(3):745-754. PubMed ID: 34075559
[TBL] [Abstract][Full Text] [Related]
32. Development and Validation of Interpretable Machine Learning Models for Clinically Significant Prostate Cancer Diagnosis in Patients With Lesions of PI-RADS v2.1 Score ≥3.
Ruan M; Liu Y; Yao K; Wang K; Fan Y; Wu S; Wang X
J Magn Reson Imaging; 2024 Feb; ():. PubMed ID: 38363125
[TBL] [Abstract][Full Text] [Related]
33. Performing Precise Biopsy in Naive Patients With Equivocal PI-RADS, Version 2, Score 3, Lesions: An MRI-based Nomogram to Avoid Unnecessary Surgical Intervention.
Zhang Y; Zeng N; Zhang FB; Rui Huang YX; Tian Y
Clin Genitourin Cancer; 2020 Oct; 18(5):367-377. PubMed ID: 32771334
[TBL] [Abstract][Full Text] [Related]
34. Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic-Based Model vs. PI-RADS v2.
Chen T; Li M; Gu Y; Zhang Y; Yang S; Wei C; Wu J; Li X; Zhao W; Shen J
J Magn Reson Imaging; 2019 Mar; 49(3):875-884. PubMed ID: 30230108
[TBL] [Abstract][Full Text] [Related]
35. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy.
Taghipour M; Ziaei A; Alessandrino F; Hassanzadeh E; Harisinghani M; Vangel M; Tempany CM; Fennessy FM
Abdom Radiol (NY); 2019 Apr; 44(4):1520-1527. PubMed ID: 30361870
[TBL] [Abstract][Full Text] [Related]
36. Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer.
Li M; Yang L; Yue Y; Xu J; Huang C; Song B
Front Oncol; 2020; 10():631831. PubMed ID: 33680954
[TBL] [Abstract][Full Text] [Related]
37. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
[TBL] [Abstract][Full Text] [Related]
38. Fully automated detection and localization of clinically significant prostate cancer on MR images using a cascaded convolutional neural network.
Zhu L; Gao G; Zhu Y; Han C; Liu X; Li D; Liu W; Wang X; Zhang J; Zhang X; Wang X
Front Oncol; 2022; 12():958065. PubMed ID: 36249048
[TBL] [Abstract][Full Text] [Related]
39. Predicting clinically significant prostate cancer with a deep learning approach: a multicentre retrospective study.
Zhao L; Bao J; Qiao X; Jin P; Ji Y; Li Z; Zhang J; Su Y; Ji L; Shen J; Zhang Y; Niu L; Xie W; Hu C; Shen H; Wang X; Liu J; Tian J
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):727-741. PubMed ID: 36409317
[TBL] [Abstract][Full Text] [Related]
40. Sub-differentiation of PI-RADS 3 lesions in TZ by advanced diffusion-weighted imaging to aid the biopsy decision process.
Zhou KP; Huang HB; Bu C; Luo ZX; Huang WS; Xie LZ; Liu QY; Bian J
Front Oncol; 2023; 13():1092073. PubMed ID: 36845749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
